Q2 2026 Orthofix Medical Inc Earnings Call Transcript
Key Points
- Orthofix Medical Inc (OFIX) delivered 5% pro forma constant currency net sales growth in Q2 2026, with double-digit growth in global limb reconstruction and spine fixation.
- The restoration of Medicare reimbursement for bone growth stimulators removes a meaningful headwind for the therapeutic solutions business and improves second-half visibility.
- Biologics showed a marked improvement, moving from double-digit declines last year to approximately flat performance in Q2, the second consecutive quarter of improved year-over-year performance.
- The company secured a strategic European distributor arrangement that is expected to contribute approximately $15 million of incremental net sales in 2026, funded by the distributor for MDR certification.
- Orthofix Medical Inc (OFIX) increased its full-year adjusted EBITDA guidance range to $95 million to $98 million, reflecting ongoing cost actions and operational progress.
- The launch of Access Team 2.0, an award-winning bone growth therapy device with enhanced ease of use and mobile app compatibility, strengthens the therapeutic solutions value proposition.
- Orthofix Medical Inc (OFIX) experienced a steeper-than-expected decline among smaller U.S. spine distributors, whose productivity has been below expectations for several quarters.
- The company faces a $22 million net sales headwind in 2027 due to the timing of the European distributor MDR arrangement, which is a discrete benefit in 2026.
- Adjusted gross margin was negatively impacted by an unfavorable geographic mix during the quarter, coming in at 71.7%.
- Profitability was impacted by credit losses in certain international markets and continued investment in key launches, despite ongoing cost optimization initiatives.
- U.S. limb reconstruction growth was below expectations, as the company is still building the commercial infrastructure required to consistently convert clinical interest into revenue.
- The European distributor arrangement creates a temporary free cash flow timing headwind in 2026, as some cash receipts are projected to occur in 2027 while inventory-related cash outflows occur this year.
Thank you for standing by. At this time, I would like to welcome everyone to the OrthoFix Second Quarter 2026 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press followed by the number one on your telephone keypad.
If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Julie Dewey.
Thank you, and good morning, everyone. Welcome to OrthoFix's second quarter 2026 earnings call. I'm Julie Dewey, OrthoFix's Chief IR and Communications Officer. Joining me today are President and Chief Executive Officer Massimo Calafiore and Chief Financial Officer Julie Andrews.
Earlier today, Orthofix released its financial results for the second quarter ended June 30th, 2026. A copy of the press release and supplemental presentation are available on our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
